Subsea 7 - 4Q22 and FY22 conference call notification
Luxembourg –18 January 2023 – Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) will publish its fourth quarter results for the period ended 31 December 2022 on 2 March 2023 at 08:00 CET.
From 08:00 CET the results announcement and presentation will be available at www.subsea7.com.
A conference call and simultaneous webcast for the investment community will be held on 2 March 2023 at 13:00 CET.
Conference call information:
Date: 2 March 2023
Time: 12:00 GMT / 13:00 CET
Conference call registration:
Phone dial-in: https://register.vevent.com/register/BI168b055453614ec7809c9f72edb6876c
Subsea7 is a global leader in the delivery of offshore projects and services for the evolving energy industry creating sustainable value by being the industry’s partner and employer of choice in delivering the efficient offshore solutions the world needs.
Subsea7 is listed on the Oslo Børs (SUBC), ISIN LU0075646355, LEI 222100AIF0CBCY80AH62.
Head of Investor Relations
Subsea 7 S.A.
Tel +44 20 8210 5568
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Årsrapport for 2022 - Selskabsmeddelelse nr. 1/202327.3.2023 23:07:48 CEST | pressemeddelelse
ÅRSRAPPORT FOR 2022 UDBYTTESTRØM OG LIKVIDITET BEDRE END FORVENTET, TIL TRODS FOR SVÆRE MARKEDER PÅVIRKET AF COVID Hovedpunkter for 2022 - Koncernen Resultat for året blev et tab på DKK 1,5 mio. (DKK -0,5 mio.).Totale pengestrømme for året på DKK -9,1 mio. (2021: positive pengestrømme på DKK 0,8 mio.)Likvide midler pr. 31. december 2022 på DKK 13,0 (DKK 21,9 mio.), heraf DKK 3,5 mio. i moderselskabet EAC Invest, DKK 5,8 mio. i Thailand og DKK 3,7 mio. indestår i Kina og er ikke til umiddelbar disposition for EAC Invest koncernen udenfor Kina.Udbytter fra investeringer udgjorde DKK 3,4 mio., og var lidt højere end oprindeligt forventet.Thai Poly Acrylic var i 2022 hårdt ramt af efterdønninger fra Covid-19 og stigende priser på råmaterialer, hvilket påvirkede salget og resultatet var betydeligt under forventning.Udbyttebetaling på DKK 1.000 pr. aktie og i alt DKK 10 mio. blev gennemført i april 2022. Forventninger for 2023 - Koncernen Forventede driftsomkostninger (primært driftsresultat
Nyxoah Raises $3 Million from an At-the-Market Equity Offering27.3.2023 22:05:00 CEST | Press release
INSIDE INFORMATION REGULATED INFORMATION Nyxoah Raises $3 Million from an At-the-Market Equity Offering Mont-Saint-Guibert, Belgium – March 27, 2023, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company raised $2.8 million in gross proceeds pursuant to the Company’s $50 million at-the-market ("ATM") program established on December 22, 2022 at an issue price equal to the market price on the Nasdaq Global Market at the time of the sale. The shares were purchased by historical Nyxoah shareholder Cochlear Limited, and the proceeds will be used for general corporate purposes. The ordinary shares described above were sold pursuant to the Company’s shelf registration statement on Form F-3 (File No. 333-268955), previously filed with the Securities and Exchange Commission (“SEC
Convocation of the 2023 Annual General Meeting of Shareholders and Proposed Resolutions27.3.2023 20:30:00 CEST | Press release
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014). EINDHOVEN, Pays-Bas et LAUSANNE, Suisse, et BOSTON, MA, Etats-Unis, March 27, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD) (the Company), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today has convened the 2023 Annual General Meeting of Shareholders (AGM), including the resolutions to be submitted for adoption at the AGM, which will be held in Amsterdam, the Netherlands, on May 8, 2023. The resolutions, proposed by the Board, to be submitted for adoption at the AGM, are as follows: Adoption of the Company’s statutory annual accounts for the financial year ended December 31, 2022, prepared in accordance with International Financial Reporting Standards (IFRS-EU). The 2022 statutory accounts were filed with the Netherlands Authority for the Fina
ONWARD Reports 2022 Full Year Financial and Operating Results27.3.2023 20:00:00 CEST | Press release
Company also Provides Business Update and Outlook for 2023 - Conference Call and Webcast (in English) March 28, 2023, at 2:00 PM CEST/8:00 AM EDT THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, the Netherlands, LAUSANNE, Switzerland & BOSTON, MA USA, March 27, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announces its 2022 financial and operating results. The full Annual Report is available here, on the Company’s website in the Investors section (https://ir.onwd.com), and on the website of the Netherlands Authority for the Financial Markets (www.afm.nl). “I am proud of the volume and significance of our team’s achievements as we prepare for commercialization of our first therapy in late 2023 or early 2024,” said Dave Marver, CEO
Nokia Corporation: Repurchase of own shares on 27.03.202327.3.2023 20:00:00 CEST | Press release
Nokia Corporation Stock Exchange Release 27 March 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 27.03.2023 Espoo, Finland – On 27 March 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL284,4184.39CEUX14,3074.40AQEU2904.39TQEX9854.38Total300,0004.39 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023 and en